| Original language | English (US) |
|---|---|
| Article number | 100152 |
| Journal | Schizophrenia Research: Cognition |
| Volume | 17 |
| DOIs | |
| State | Published - Sep 2019 |
Keywords
- Attenuated psychosis syndrome
- Cognitive impairment
- Functional capacity
- Real-world functioning
ASJC Scopus subject areas
- Cognitive Neuroscience
- Psychiatry and Mental health
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Functional deficits in attenuated psychosis syndrome and related conditions : Current and future treatment options. / Harvey, Philip D.; Jones, Mackenzie Taylor.
In: Schizophrenia Research: Cognition, Vol. 17, 100152, 09.2019.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Functional deficits in attenuated psychosis syndrome and related conditions
T2 - Current and future treatment options
AU - Harvey, Philip D.
AU - Jones, Mackenzie Taylor
N1 - Funding Information: Funding for writing assistance for this article was provided by Boehringer Ingelheim International GmbH. The sponsor was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations. No financial support of any kind was given to the authors. Editorial support in the form of initial preparation of the outline based on input from all authors, and collation and incorporation of author feedback to develop subsequent drafts, assembling tables and figures, copy-editing and referencing was provided by Sam Halliwell, PhD of Fishawack Communications Ltd. which was funded by Boehringer Ingelheim GmbH. The opinions expressed in this manuscript are the personal views of the Authors and may not be understood or quoted as being made on behalf of or reflecting the position of any of the Institutions or Companies for which they work, have worked, or have collaborated with. The mention of commercial products, their sources, or their use in connection with material reported herein is not to be construed as either an actual or implied endorsement of such products to any Public Department or Health and/or Payer Services. PDH has served as a consultant in the past year to Alkermes, Boehringer-Ingelheim, Lundbeck, Otsuka America, Sanofi, Sunovion Pharmaceuticals, Takeda, and Teva, and has received research grants from Takeda and Stanley Medical Research Foundation. MTJ reports no potential biomedical conflicts of interest. Funding Information: PDH has served as a consultant in the past year to Alkermes, Boehringer-Ingelheim, Lundbeck, Otsuka America, Sanofi, Sunovion Pharmaceuticals, Takeda, and Teva, and has received research grants from Takeda and Stanley Medical Research Foundation. MTJ reports no potential biomedical conflicts of interest. Funding Information: Editorial support in the form of initial preparation of the outline based on input from all authors, and collation and incorporation of author feedback to develop subsequent drafts, assembling tables and figures, copy-editing and referencing was provided by Sam Halliwell, PhD of Fishawack Communications Ltd., which was funded by Boehringer Ingelheim GmbH.
PY - 2019/9
Y1 - 2019/9
KW - Attenuated psychosis syndrome
KW - Cognitive impairment
KW - Functional capacity
KW - Real-world functioning
UR - http://www.scopus.com/inward/record.url?scp=85065559333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065559333&partnerID=8YFLogxK
U2 - 10.1016/j.scog.2019.100152
DO - 10.1016/j.scog.2019.100152
M3 - Review article
AN - SCOPUS:85065559333
VL - 17
JO - Schizophrenia Research: Cognition
JF - Schizophrenia Research: Cognition
SN - 2215-0013
M1 - 100152
ER -